05
Pharmaceuticals for use in the prevention and treatment of
neurologic, genetic, psychologic, and psychiatric diseases
and disorders
35
Promoting awareness of patient support offerings for
neurologic, genetic, psychologic, and psychiatric diseases
and disorders (term considered too vague by the
International Bureau - Rule 13 (2) (b) of the Regulations);
medical referrals
42
Scientific and industrial biotechnological and biomedical
research; chemical, biochemical and molecular biological
analyses; medical testing, namely, in vitro and in vivo
preclinical testing of potential drugs (term considered too
vague by the International Bureau - Rule 13 (2) (b) of the
Regulations); consultation related thereto; providing
medical and scientific research information in the field of
pharmaceuticals and clinical trials
44
Medical consulting with respect to neurologic, genetic,
psychologic, and psychiatric diseases and disorders,
including Rett syndrome and its identification and
treatment; providing online information for health care
providers, caregivers, and patients in the field of
neurologic, genetic, psychologic, and psychiatric diseases
and disorders; medical informational support services,
namely, providing information about the benefits of
diagnostic tools, medical information regarding disease
diagnosis, identification, treatment, and management, and
healthcare-related information to patients, caregivers, and
healthcare professionals all related to neurologic, genetic,
psychologic, and psychiatric diseases and disorders
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen